Schoch Charles 4

What Happened

• Charles Schoch, Chief Financial Officer of Candel Therapeutics (CADL), received a derivative award on January 26, 2026 to acquire 232,000 shares. The Form 4 lists the acquisition price as $0.00 (derivative award/option), indicating a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-26; Form 4 filed: 2026-01-28 (appears timely).
• Transaction type: Award/Grant (derivative). Amount: 232,000 underlying shares; price reported $0.00.
• Shares owned following the transaction: not specified in the provided filing.
• Footnote: the option is subject to time-based vesting — vests and becomes exercisable in 48 equal monthly installments beginning January 26, 2026, contingent on continued service.

Context

• This was a compensation award (an option-style derivative), not a cash purchase or sale. The award vests over four years, so only a portion will become exercisable each month if Schoch remains employed. Such grants are common executive compensation and do not represent an immediate market buy signal.